Richard Riedel

Overview:

Novel therapies for soft tissue and bone sarcomas

Positions:

Associate Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2000

Thomas Jefferson University

Resident in Medicine, Medicine

Duke University

Fellow in Hematology-Oncology, Medicine

Duke University

Fellow in Hematology-Oncology, Medicine

Duke University

Grants:

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Administered By
Duke Cancer Institute
Awarded By
Blueprint Medicines Corporation
Role
Principal Investigator
Start Date
End Date

Dissecting Mechanisms of Metastasis Through Comparative Systems Genetics

Administered By
Radiation Oncology
Awarded By
National Institutes of Health
Role
Investigator
Start Date
End Date

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Administered By
Duke Cancer Institute
Awarded By
SpringWorks Therapeutics
Role
Principal Investigator
Start Date
End Date

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib

Administered By
Duke Cancer Institute
Awarded By
Deciphera Pharmaceuticals, LLC
Role
Principal Investigator
Start Date
End Date

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of MB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Subjects Following First-line Systemic Anti-cancer Therapy

Administered By
Duke Cancer Institute
Awarded By
Immune Design Corp.
Role
Principal Investigator
Start Date
End Date

Publications:

LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT)

Authors
Kasper, B; Ratan, R; Alcindor, T; Schoeffski, P; van der Graaf, WTA; Wilky, BA; Riedel, RF; Lim, A; Smith, LM; Moody, S; Attia, S; Chawla, SP; D'Amato, G; Federman, N; Van Tine, P; Van Tine, BA; Vincenzi, B; Kummar, S; Gounder, MM
MLA Citation
Kasper, B., et al. “LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT).” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S1435–36. Crossref, doi:10.1016/j.annonc.2022.08.075.
URI
https://scholars.duke.edu/individual/pub1560051
Source
crossref
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S1435
End Page
S1436
DOI
10.1016/j.annonc.2022.08.075

Sharing the Sandbox: Implementation and Results From a Fully Integrated Palliative Care/Medical Oncology Rounding Model for Inpatient Cancer Care (SA512)

Authors
Jones, C; Riedel, R; Slusser, K; Desai, D; Galanos, A
MLA Citation
Jones, Christopher, et al. “Sharing the Sandbox: Implementation and Results From a Fully Integrated Palliative Care/Medical Oncology Rounding Model for Inpatient Cancer Care (SA512).” Journal of Pain and Symptom Management, vol. 45, no. 2, Elsevier BV, 2013, pp. 400–01. Crossref, doi:10.1016/j.jpainsymman.2012.10.256.
URI
https://scholars.duke.edu/individual/pub938896
Source
crossref
Published In
Journal of Pain and Symptom Management
Volume
45
Published Date
Start Page
400
End Page
401
DOI
10.1016/j.jpainsymman.2012.10.256

Bone sarcomas

MLA Citation
Larrier, Nicole, et al. “Bone sarcomas.” CANCER CONSULT: EXPERTISE FOR CLINICAL PRACTICE, 2014, pp. 689–95.
URI
https://scholars.duke.edu/individual/pub1548430
Source
wos-lite
Published Date
Start Page
689
End Page
695

A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results.

BACKGROUND: Regorafenib is one of several FDA-approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype-specific data regarding kinase inhibitor activity in sarcomas. We report results of a single arm, phase II trial of regorafenib in advanced Ewing family sarcomas. METHODS: Patients with metastatic Ewing family sarcomas (age ≥ 18, ECOG 0-2, good organ function) who had received at least one line of therapy and experienced progression within 6 months of registration were eligible. Prior kinase inhibitors were not allowed. The initial dose of regorafenib was 160 mg oral days 1-21 of a 28-day cycle. The primary endpoint was estimating progression-free rate (PFR) at 8 weeks employing RECIST 1.1. RESULTS: Thirty patients (median age, 32 years; 33% women [10 patients]; bone primary, 40%; extraskeletal primary, 60%) enrolled at 14 sites. The most common grade 3 or higher toxicities were hypophosphatemia (5 grade 3, 1 grade 4), hypertension (2 grade 3), elevated ALT (2 grade 3). Sixteen patients required dose reductions, most often for hypophosphatemia (n = 7 reductions in 6 patients); two stopped regorafenib for toxicity. There was one death unrelated to treatment in the 30-day post-study period. Median progression-free survival (PFS) was 14.8 weeks (95% CI 7.3-15.9); PFR at 8 weeks by Kaplan-Meier analysis was 63% (95% CI 46-81%). The RECIST 1.1 response rate was 10%. Median OS was 53 weeks (95% CI 37-106 weeks). CONCLUSIONS: Regorafenib has modest activity in the Ewing family sarcomas. Toxicity was similar to that seen in approval studies.
Authors
Attia, S; Bolejack, V; Ganjoo, KN; George, S; Agulnik, M; Rushing, D; Loggers, ET; Livingston, MB; Wright, J; Chawla, SP; Okuno, SH; Reinke, DK; Riedel, RF; Davis, LE; Ryan, CW; Maki, RG
MLA Citation
URI
https://scholars.duke.edu/individual/pub1532411
PMID
35950293
Source
pubmed
Published In
Cancer Medicine
Published Date
DOI
10.1002/cam4.5044

nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.

Authors
Dickson, MA; Ravi, V; Riedel, RF; Ganjoo, KN; Van Tine, BA; Chugh, R; Cranmer, LD; Gordon, EM; Chen, JL; Murphy, MC; Schmid, AN; Desai, N; Palma, NA; Kwiatkowski, DJ; Wagner, AJ
URI
https://scholars.duke.edu/individual/pub1555396
Source
wos-lite
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
40
Published Date